Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Drug resistance in cancer poses a significant clinical challenge.
• Developing novel therapeutic strategies is crucial for overcoming resistance.
• Thiazolidinone compounds have shown potential in cancer treatment.

Purpose of the Study:

• To identify synergistic combinations of thiazolidinone compounds for cancer therapy.
• To investigate the molecular mechanisms underlying the efficacy of the identified combination.
• To evaluate the therapeutic potential against drug-resistant cancer models.

Main Methods:

• Screening of 100 thiazolidinone compound combinations.
• In vitro cell growth inhibition assays (H460 and H460/TaxR cells).
• In vivo xenograft mouse model studies (H460/TaxR).
• Whole genome microarray analysis.
• Western blot analysis for key proteins and signaling pathways.

Main Results:

• One combination (M4) demonstrated synergistic inhibition of cancer cell and tumor growth.
• Microarray analysis revealed upregulation of genes in microtubule regulation, cell cycle arrest, and apoptosis.
• Compounds in M4 function as microtubule polymerization or histone deacetylase inhibitors.
• Synergistic action leads to G2/M cell cycle arrest, apoptosis, and modulation of key proteins (p53, p21, caspases, JNK, p38, Akt).

Conclusions:

• The thiazolidinone combination M4 offers a promising strategy for overcoming drug resistance in cancer.
• Targeting multiple pathways, including microtubule dynamics and epigenetic regulation, is effective.
• This approach provides a foundation for developing new combination therapies for resistant cancers.